Cost-effectiveness of pre-emptive pharmacogenetic testing: An umbrella review
PLOS One · 2026
DOI: 10.1371/journal.pone.0338277 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS One, 2026. Verfasst von Taichi Ochi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherla…. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Cost-Effectiveness Analysis, Pharmacogenomic Testing, Pharmacogenetics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Consortia have been established and published pharmacogenetic-specific guidelines with pharmacotherapeutic recommendations. While these consortia and their guidance addressed important information gaps, implementation barriers, including determining the cost-effectiveness for further implementation in healthcare practice, remain unaddressed.
Methods
The authors systematically searched PubMed, EMBASE, and Web of Science from inception to March 2023 for systematic reviews of pharmacoeconomic evaluations of PGx studies. A second search was conducted in October 2025. The studies from the databases were imported into Rayyan for screening the title and abstract, based on the inclusion and exclusion criteria. The umbrella review was conducted in adherence to the proposal registered in PROSPERO (CRD42023408535). The quality of eligible systematic reviews was assessed by the AMSTAR-2 checklist.
Results
From the initial screening of the three databases, title and abstract screening, and full paper readings, 17 systematic reviews were included for the umbrella review. The evidence points to the fact that with an increasing number of evaluations, the evidence for the cost-effectiveness of PGx testing was increasing over the years. From the included reviews, data from 211 unique evaluation studies were extracted. 150 (71.1%) studies reported that PGx testing was cost-effective. The most frequently used type of economic evaluation was cost-utility analysis (n = 78). Most economic evaluations investigated the pharmacogene CYP2C19 (n = 46), followed closely by CYP2C9/VKORC1 (n = 28).
Conclusions
The number of economic evaluations demonstrating cost-effectiveness of PGx testing has increased over the years. However, the majority of these evaluations were conducted in a small number of countries. When interpreting findings for different countries, the evaluations need to be adjusted on a case-by-case basis for applicability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands.
- University of Groningen Library, University of Groningen, Groningen, the Netherlands.
- Division Laboratories, Pharmacy and Biomedical Genetics, Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, the Netherlands.
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
- Center for Nutrition, Prevention and Health Services Research, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
ORCID-Profile: Taichi Ochi, Manon G den Uil
Zitieren
APA
Ochi, T., den Uil, M. G., Piazza, G., Frederix, G. W. J., Hak, E., Deneer, V. H. M., & Feenstra, T. L. (2026). Cost-effectiveness of pre-emptive pharmacogenetic testing: An umbrella review. PLOS One. https://doi.org/10.1371/journal.pone.0338277
Vancouver
Ochi T, den Uil MG, Piazza G, Frederix GWJ, Hak E, Deneer VHM, et al. Cost-effectiveness of pre-emptive pharmacogenetic testing: An umbrella review. PLOS One. 2026. doi:10.1371/journal.pone.0338277
BibTeX
@article{Ochi2026,
author = {Ochi, Taichi and den Uil, Manon G and Piazza, Greta and Frederix, Geert W J and Hak, Eelko and Deneer, Vera H M and Feenstra, Talitha L},
title = {Cost-effectiveness of pre-emptive pharmacogenetic testing: An umbrella review},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0338277}
}
EUVIMED